Cadrenal Therapeutics, Inc.
CVKD
$5.47
$0.285.40%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 38.50% | 97.26% | 125.35% | 112.42% | 90.27% |
| Depreciation & Amortization | 263.16% | 219.05% | 191.30% | 183.33% | -5.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.81% | 84.68% | 117.25% | 153.13% | 43.60% |
| Operating Income | -22.81% | -84.68% | -117.25% | -153.13% | -43.60% |
| Income Before Tax | -24.28% | -89.08% | -126.20% | -164.78% | -27.45% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.28% | -89.08% | -126.20% | -164.78% | -27.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.28% | -89.08% | -126.20% | -164.78% | -27.45% |
| EBIT | -22.81% | -84.68% | -117.25% | -153.13% | -43.60% |
| EBITDA | -22.77% | -84.64% | -117.23% | -153.12% | -43.61% |
| EPS Basic | 29.82% | -25.29% | -65.00% | -104.72% | 9.64% |
| Normalized Basic EPS | 29.83% | -25.29% | -65.00% | -104.72% | -0.13% |
| EPS Diluted | 29.82% | -25.29% | -65.00% | -104.72% | 9.64% |
| Normalized Diluted EPS | 29.83% | -25.29% | -65.00% | -104.72% | -0.13% |
| Average Basic Shares Outstanding | 80.68% | 63.04% | 43.81% | 31.55% | 22.72% |
| Average Diluted Shares Outstanding | 80.68% | 63.04% | 43.81% | 31.55% | 22.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |